JPRN-jRCT2031220181进行中（未招募）3 期
A phase III confirmatory study of KLH-2109 in uterine fibroids patient with menorrhagia and pain
Shimizu Yoshitaka0 个研究点目标入组 78 人开始时间: 2022年7月5日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 78
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Japanese uterine fibroid patients
- •- Premenopausal female patient over 20 years old
- •- Patients confirmed by transvaginal ultrasonography to have at least 1 myoma that meet all of the following conditions:
- •- Larger than a certain standard
- •- No calcification
- •- Not receiving surgical treatment
- •- Patients with a normal menstrual cycle
- •- Patients diagnosed with menorrhagia
- •- Patients with pain symptoms associated with uterine fibroids
排除标准
- •- Patients with complication or history of blood system diseases (salasemia, sickle erythrocyte anemia, folic acid deficiency, coagulation disorder, etc.) (excluding iron deficiency anemia and latent iron deficiency anemia)
- •- Patients with lower abdominal pain due to irritable bowel syndrome or lower abdominal pain due to severe interstitial cystitis
- •- Patients with undiagnosed abnormal genital bleeding
研究者
相似试验
进行中（未招募）
3 期
A clinical study of KLH-2109 in uterine fibroids patient with menorrhagiaterine fibroidJPRN-jRCT2031220180Shimizu Yoshitaka264
未知
2 期
Phase II Study of KRP-209Subjective tinnitusJPRN-jRCT2080221608Kyorin Pharmaceutical Co.,LTD400
未知
3 期
A phase III study of KW-2246JPRN-jRCT2080221423Kyowa Hakko Kirin Co., Ltd.
进行中（未招募）
1 期
An Investigational Immunotherapy Study of NKTR-214 and Nivolumab vs Nivolumab alone in Participants With Previously Untreated Inoperable or Metastatic Melanomantreated unresectable or metastatic melanomaMedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864EUCTR2018-001423-40-ESBristol-Myers Squibb International Corporation1,020
进行中（未招募）
1 期
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab alone in Participants With Previously Untreated Inoperable or Metastatic Melanomantreated unresectable or metastatic melanomaMedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2018-001423-40-NLBristol-Myers Squibb International Corporation764